Auctus Biologics is a biotechnology company that develops antibody mimetics for therapeutic and diagnostic applications.
Auctus Biologics is a pre-clinical biotechnology company that develops antibody mimetics for therapeutic and diagnostic applications.Antibodies are the most prolific biologics in clinical environments because of their ability to bind targets with high affinity and specificity. However, antibodies also carry liabilities. They are often unstable and require costly cold-chain management to reach their destinations in active form. Because of their fragility, antibodies typically cannot be used in extreme environments like the gastrointestinal tract and can require lengthy infusions to administer to patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 9, 2022 | Grant | $228.69K | 1 | National Science Foundation | — | Detail |
Sep 24, 2018 | Seed | $1.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
Grapeseed.Bio | — | Seed |